Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new enhanced monofocal lens is impressing patients and surgeons alike. A real-world study of Bausch + Lomb's enVista Aspire IOL across 57 U.S. sites found that over 96% of patients rated their distance vision as good to excellent, and more than 50% were spectacle-free for near tasks — a remarkable result for a lens not designed for near vision. Minimal glare, halos, and starbursts rounded out an impressive performance profile.
A cataract lens that over-delivers on expectations
Bausch + Lomb's enVista Aspire, an enhanced monofocal intraocular lens (IOL), took center stage at the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in London. Results from a prospective, multicenter real-world study involving 310 patients across 57 U.S. sites showed the lens delivers broad depth of focus, sharp distance vision, and notably strong near vision — all with minimal optical side effects like glare and halos.
The lens uses higher-order aspheric coefficients on its posterior surface to extend depth of focus without sacrificing distance clarity. A toric version is also available to address astigmatism, achieving a 77% reduction from pre- to post-op with a mean residual astigmatism of just 0.32 D.
By the Numbers
Why it matters: For surgeons counseling cataract patients, the enVista Aspire offers a compelling middle ground — enhanced visual performance without the dysphotopsia trade-offs often associated with multifocal lenses. The real-world data suggest that setting conservative expectations may actually lead to highly satisfied patients.
